Table 1 Posterior predicted median peak levels (BAU/mL) and half-lives (days) with 95% credible intervals in participants received one vaccination with prior infection, two vaccinations without prior infection, and one vaccination without prior infection, by vaccine type.
Peak level (BAU/mL) | Half-life (days) | |||||||
|---|---|---|---|---|---|---|---|---|
Vaccine | Age | Group | One dose with prior infection | Two doses without prior infection (from ref. 16) | One dose without prior infection | One dose with prior infection | Two doses without prior infection (from ref. 16) | One dose without prior infection |
ChAdOx1 | 50 | White female | 447 (432–462) | 160 (157–162) | 84 (83–85) | 85 (76–97) | 81 (79–83) | 93 (89–99) |
50 | White male | 416 (402–431) | 154 (152–157) | 78 (77–80) | 77 (70–87) | 81 (79–83) | 84 (80–89) | |
50 | Non-white females | 637 (607–670) | 201 (195–207) | 120 (115–125) | 75 (65–88) | 73 (70–76) | 81 (72–92) | |
50 | Non-white males | 594 (565–625) | 195 (189–201) | 112 (107–116) | 69 (60–80) | 73 (70–77) | 74 (66–83) | |
BNT162b2 | 50 | White female | 432 (416–449) | 974 (942–1009) | 168 (165–172) | 266 (175–544) | 52 (50–53) | 46 (44–47) |
50 | White male | 397 (382–413) | 836 (807–864) | 155 (152–158) | 256 (168–500) | 51 (50–53) | 45 (43–47) | |
50 | Non-white females | 517 (487–549) | 1114 (1045–1190) | 202 (192–212) | 204 (127–505) | 51 (48–54) | 43 (39–48) | |
50 | Non-white males | 476 (448–506) | 955 (894–1019) | 186 (176–195) | 198 (124–470) | 51 (48–54) | 43 (39–48) | |
mRNA-1273 | 50 | White female | 505 (413–619) | 278 (245–317) | 768 (75-Not estimable) | 80 (51–178) | ||
50 | White male | 447 (365–546) | 246 (218–278) | 169 (57-Not estimable) | 59 (43–97) | |||
50 | Non-white females | 462 (348–615) | 255 (200–325) | Not estimable (86-Not estimable) | 184 (50-Not estimable) | |||
50 | Non-white males | 409 (306–544) | 225 (176–288) | Not estimable (62-Not estimable) | 100 (41-Not estimable) | |||
